GLP-1 Maintenance Dosing: Evidence-Based Guidance for Long-Term Weight Loss

Medical Writer: Dr. Xavier Laucirica, MD, MPH, DHS

Introduction

GLP-1 receptor agonists and dual incretin therapies have significantly changed the landscape of obesity treatment. Medications such as semaglutide and tirzepatide have demonstrated substantial weight loss outcomes in randomized clinical trials. However, an important clinical question remains: what is the appropriate long-term strategy after initial weight loss is achieved?

This article provides a structured, evidence-based review of GLP-1 maintenance dosing, drawing on FDA-approved prescribing information and randomized clinical trials. All conclusions are derived directly from verifiable sources, with no speculation or unsupported claims.

What Is GLP-1 Maintenance Dosing?

GLP-1 maintenance dosing refers to the continued use of an FDA-approved therapeutic dose after dose escalation is complete, to sustain weight loss and ongoing metabolic benefits.

In obesity medicine, a maintenance dose does not mean a minimal or reduced dose. It refers specifically to the dose supported by regulatory approval and clinical evidence for long-term treatment.

This concept is consistent with evidence-based obesity treatment, which recognizes obesity as a chronic, relapsing disease requiring ongoing management.

FDA-Approved Maintenance Doses

The most reliable source for defining GLP-1 maintenance dosing is FDA-approved prescribing information.

Semaglutide (Wegovy)

According to the FDA label, the recommended maintenance dosing for semaglutide (Wegovy) is:

• 2.4 mg once weekly (recommended maintenance dose)

• 1.7 mg once weekly (alternative maintenance dose based on tolerability)

Tirzepatide (Zepbound)

According to the FDA label, the approved maintenance dosing for tirzepatide (Zepbound) includes:

• 5 mg once weekly

• 10 mg once weekly

• 15 mg once weekly

The FDA label explicitly states that 2.5 mg is an initiation dose and not a maintenance dose.

Wegovy vs Zepbound Dosing

Wegovy vs Zepbound dosing differs in their approved maintenance ranges. Wegovy uses a narrower range (1.7 mg to 2.4 mg weekly), while Zepbound allows multiple maintenance levels (5 mg to 15 mg weekly). These differences are explicitly defined in FDA labeling and should guide clinical decision-making.

Why GLP-1 Maintenance Dosing Is Necessary

Obesity as a Chronic Disease

Obesity is recognized as a chronic, relapsing condition. This classification is supported by clinical evidence demonstrating that stopping treatment often leads to the reversal of benefits.

This is not theoretical. It is demonstrated in randomized clinical trials evaluating weight regain after GLP-1 discontinuation.

Evidence From Clinical Trials

STEP 4 Trial (Semaglutide)

Study design: randomized withdrawal trial following a 20-week semaglutide run-in phase.

Results:

• Continued semaglutide group: additional 7.9 percent weight loss

• Placebo (withdrawal) group: 6.9 percent weight regain

• Difference: 14.8 percentage points

Interpretation:

• Continued GLP-1 maintenance dosing maintained and enhanced weight loss

• Discontinuation resulted in significant weight regain after GLP-1 therapy

SURMOUNT-4 Trial (Tirzepatide)

Study design: randomized withdrawal after a 36-week lead-in period.

Results:

• Continued tirzepatide: 5.5 percent additional weight loss

• Placebo group: 14.0 percent weight regain

• Difference: 19.4 percentage points

Additional findings:

• 89.5 percent maintained at least 80 percent of weight loss (continued group)

• 16.6 percent maintained at least 80 percent (placebo group)

These findings provide strong evidence for Tirzepatide-mediated weight-loss maintenance through continued therapy.

STEP 1 Extension (Semaglutide Withdrawal)

After discontinuation of semaglutide:

• Participants regained approximately two-thirds of their prior weight loss within one year

This study provides direct evidence of weight regain after GLP-1 discontinuation.

Step-by-Step Evidence-Based Conclusion

1. FDA labels define approved maintenance dosing for semaglutide and tirzepatide

2. Randomized withdrawal trials consistently show:

   • Continued treatment leads to sustained or increased weight loss

   • Discontinuation leads to significant weight regain after GLP-1

3. Long-term extension studies confirm that weight regain occurs after stopping therapy

Conclusion:

GLP-1 maintenance dosing is a required component of evidence-based obesity treatment when the goal is sustained weight loss.

Are Lower or “Microdoses” Evidence-Based?

Some programs promote reduced or “microdosing” strategies for long-term maintenance.

Based on available evidence:

• No randomized controlled trials validate microdosing as an effective maintenance strategy

• No FDA-approved labeling supports non-standard maintenance dosing outside approved ranges

Conclusion:

I cannot confirm that microdosing strategies are evidence-based for long-term weight maintenance, as no high-quality clinical trial data or regulatory guidance supports this approach.

Individualization Within Approved Maintenance Dosing

FDA labeling allows dose selection based on:

• Treatment response

• Tolerability

This means:

• Some patients may maintain weight loss on lower approved doses

• Others may require higher doses within approved ranges

However, GLP-1 maintenance dosing should remain within FDA-approved parameters unless supported by high-quality evidence.

Safety Considerations for Long-Term Use

Key risks listed in FDA labeling include:

• Thyroid C-cell tumors observed in rodents (human relevance unknown)

• Acute pancreatitis

• Gallbladder disease

• Acute kidney injury is often related to dehydration

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple endocrine neoplasia syndrome type 2 (MEN 2)

Additional notes:

• Wegovy: monitoring for depression or suicidal ideation is recommended

• Zepbound: not recommended in patients with severe gastrointestinal disease such as gastroparesis

Clinical Takeaway

Based on FDA-approved labeling and randomized clinical trial evidence:

• GLP-1 medications should be treated as chronic therapy

• GLP-1 maintenance dosing involves continuing an approved therapeutic dose

• Discontinuation commonly leads to clinically significant weight regain after GLP-1

• Maintenance dose selection should be evidence-based, individualized, and monitored

Bottom Line

GLP-1 maintenance dosing is not a strategy for tapering off therapy. It is a strategy for sustaining results using evidence-based obesity treatment.

Across FDA data and randomized clinical trials, the conclusion is consistent:

• Continuing treatment maintains weight loss

• Discontinuing treatment leads to weight regain after GLP-1

---

References:

1. FDA. Wegovy (semaglutide) prescribing information (2025)

2. FDA. Zepbound (tirzepatide) prescribing information (2024)

3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021

4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024

5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022